Peter A. Pinto, M.D.

Investigator

Urologic Oncology Branch

NCI/CCR

Building 10, Hatfield CRC, Room 2W-5940
Bethesda, MD 20892

301-496-6353

pintop@mail.nih.gov

Research Topics

Dr. Pinto’s scientific mission is development of novel diagnostic and treatment modalities for localized and locally advanced prostate cancer.

Research efforts are centered on investigation of multiparametric MRI (mpMRI) in prostate cancer to improve diagnosis with mpMRI whole-mount pathology correlation and creation of a tumor-directed biopsy device; development of image-guided focal prostate cancer therapy; and evaluation of immunotherapy, molecular targeted therapy or other pharmacotherapies in the management of localized or locally advanced prostate cancer.

Biography

Dr. Pinto is an Investigator and faculty member in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, Md. Following a residency in Urologic Surgery at Long Island Jewish Medical Center - Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute, Johns Hopkins Hospital. Dr. Pinto is a Board Certified Urologic Surgeon specializing in oncology and is the Director of the Urologic Oncology Fellowship Program at the National Cancer Institute. He is nationally and internationally recognized as an expert in the minimally invasive treatment of urologic cancers, specializing in laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer.

Selected Publications

  1. Hong CW, Rais-Bahrami S, Walton-Diaz A, Shakir N, Su D, George AK, Merino MJ, Turkbey B, Choyke PL, Wood BJ, Pinto PA. Comparison of magnetic resonance imaging and ultrasound (MRI-US) fusion-guided prostate biopsies obtained from axial and sagittal approaches. BJU Int. 2015;115(5):772-9.

  2. Rais-Bahrami S, Siddiqui MM, Vourganti S, Turkbey B, Rastinehad AR, Stamatakis L, Truong H, Walton-Diaz A, Hoang AN, Nix JW, Merino MJ, Wood BJ, Simon RM, Choyke PL, Pinto PA. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies. BJU Int. 2015;115(3):381-8.

  3. Farsaci B, Jochems C, Grenga I, Donahue RN, Tucker JA, Pinto PA, Merino MJ, Heery CR, Madan RA, Gulley JL, Schlom J. Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. Int J Cancer. 2014;135(4):862-70.

  4. Logan JK, Walton-Diaz A, Rais-Bahrami S, Merino MJ, Turkbey B, Choyke PL, Pinto PA. Changes observed in multiparametric prostate magnetic resonance imaging characteristics correlate with histopathological development of chronic granulomatous prostatitis after intravesical Bacillus Calmette-Guerin therapy. J Comput Assist Tomogr. 2014;38(2):274-6.

  5. Turkbey B, Merino MJ, Gallardo EC, Shah V, Aras O, Bernardo M, Mena E, Daar D, Rastinehad AR, Linehan WM, Wood BJ, Pinto PA, Choyke PL. Comparison of endorectal coil and nonendorectal coil T2W and diffusion-weighted MRI at 3 Tesla for localizing prostate cancer: correlation with whole-mount histopathology. J Magn Reson Imaging. 2014;39(6):1443-8.


This page was last updated on June 15th, 2017